correct, could cause its results to differ materially
from those expressed or implied by such forward-looking statements.
Although Isis' forward-looking statements reflect the good faith judgment
of its management, these statements are based only on facts and factors
currently known by Isis. As a result, you are cautioned not to rely on
these forward-looking statements. These and other risks concerning Isis'
programs are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31, 2007, which is on file with the SEC.
Copies of this and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis,"
"Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its
Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals,
Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences,
Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.
ISIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Data)
Three months ended,
Research and development revenue under
collaborative agreements $20,686 $2,002
Licensing and royalty revenue 668 448
Total revenue 21,354 2,450
Research and development 26,449 19,949
Selling, general and administrative
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related medicine news :1
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites2
. Haemacure Reports Third Quarter 2007 Results3
. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion4
. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best5
. MDS Reports Third Quarter 2007 Results6
. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 20067
. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System8
. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results9
. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance10
. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion11
. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.